) is all set to announce its second quarter 2012 results before the
opening bell on July 26, 2012. The Zacks Consensus Estimate for the
second quarter of 2012 is 55 cents per share, representing a
year-over-year estimated increase of 5.8%.
MYLAN INC (MYL): Free Stock Analysis Report
To read this article on Zacks.com click here.
First Quarter 2012 Recap
Mylan's first quarter 2012 earnings (excluding special items) of 52
cents per share beat the Zacks Consensus Estimate by a penny. First
quarter earnings increased 18.2% from a year ago. Higher revenues
and gross margin expansion led to the rise in first quarter 2012
Revenues climbed 10% to $1.59 billion, just above the Zacks
Consensus Estimate of $1.58 billion. Generics sales (after
adjusting inter-segment revenues) increased 5.2% to $1.42 billion
in the reported quarter. Specialty segment sales (after adjusting
inter-segment revenues) increased 53.5% to $177 million.
(Read our full coverage on this earnings report:
Mylan Beats, Reaffirms Outlook
Agreement of Estimate Revisions
Estimate revisions for Mylan have been scarce over the last 30
days. Only 3 of the 15 analysts covering Mylan for the second
quarter of 2012 have revised their earnings estimates. While 2
analysts have reduced estimates, 1 moved in the opposite direction.
A sole analyst revised estimate downwards for fiscal 2012 over the
last 30 days.
Magnitude of Estimate Revisions
The earnings estimate for the second quarter of 2012 has remained
static over the last 30 days with the positive revisions canceling
out the downward movements.
For fiscal 2012, a downward bias was witnessed. The Zacks Consensus
Estimate for 2012 decreased by 2 cents in the last 30 days. The
Zacks Consensus Estimate for 2012 currently stands at $2.48 per
share, which is towards the higher end of the earnings guidance
range of $2.30 to $2.50 per share provided by the company. We
believe these downward revisions reflect the concerns regarding
currency headwinds and pricing pressure faced by Mylan in several
Mylan has surpassed earnings estimates in all of the last four
quarters. The company recorded a maximum positive surprise of
15.56% in the second quarter of 2011. On an average, the earnings
surprise was 7.84%.
We are encouraged by Mylan's geographic reach and product depth
along with a robust generic product pipeline.
However, we are concerned about the company's lackluster
performance in the Europe, Middle East and Africa (EMEA) region.
Additionally, with most large branded drugs due to lose patent
exclusivity in the 2017-2018 period, we have little visibility on
the growth prospects of generic companies like Mylan beyond that
Thus, we prefer to remain on the sidelines and have a Neutral
recommendation on Mylan. The stock carries a Zacks #3 Rank (Hold
rating) in the short term.